Bibliography
- Sette A, Vitiello A, Reherman B, . The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153(12):5586-92
- van der Burg SH, Visseren MJ, Brandt RM, . Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996;156(9):3308-14
- Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999;50(3-4):201-12
- Parkhurst MR, Salgaller ML, Southwood S, . Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157(6):2539-48
- Men Y, Miconnet I, Valmori D, . Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J Immunol 1999;162(6):3566-73
- Andersen ML, Ruhwald M, Nissen MH, . Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol 2003;57(1):21-7
- Brinkman JA, Fausch SC, Weber JS, . Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004;4(2):181-98
- Speiser DE, Baumgaertner P, Voelter V, . Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008;105(10):3849-54
- Huang EH, Kaufman HL. CEA-based vaccines. Expert Rev Vaccines 2002;1(1):49-63
- Ellis JM, Henson V, Slack R, . Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum Immunol 2000;61(3):334-40
- Maciel M Jr, Kellathur SN, Chikhlikar P, Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 2008;378(1):105-17
- Larsen MV, Lundegaard C, Lamberth K, . An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 2005;35(8):2295-303
- Pascolo S, Bervas N, Ure JM, . HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185(12):2043-51
- Gjertsen MK, Buanes T, Rosseland AR, . Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92(3):441-50
- Kirkwood JM, Lee S, Moschos SJ, . Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15(4):1443-51
- Rosenberg SA, Yang JC, Schwartzentruber DJ, . Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-7
- Tsuda N, Mochizuki K, Harada M, . Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004;27(1):60-72